GPR65 and Hepatic fibrosis: Interestingly, based on the fact that GPR65-KO mice were not abnormal in size, appearance and mating at the age of 12 months, together with the finding that both GPR65-KO mice and the application of GPR65 inhibitor in vivo did not exhibit any functional and morphological abnormalities (data not shown), it suggests that GPR65 is a promising and specific drug target for hepatic fibrosis, cirrhosis, or even inflammation-related diseases.